VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 71 filers reported holding VERONA PHARMA PLC in Q3 2022. The put-call ratio across all filers is 0.34 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,664,250 | -22.9% | 347,500 | 0.0% | 1.73% | +34.5% |
| Q2 2023 | $7,346,150 | -47.4% | 347,500 | -50.0% | 1.29% | -55.3% |
| Q1 2023 | $13,955,620 | -23.2% | 695,001 | 0.0% | 2.88% | -26.2% |
| Q4 2022 | $18,160,376 | +89.3% | 695,001 | -26.0% | 3.91% | +74.7% |
| Q3 2022 | $9,595,000 | +106.1% | 938,890 | -15.5% | 2.24% | +80.3% |
| Q2 2022 | $4,656,000 | -16.0% | 1,111,112 | 0.0% | 1.24% | -11.1% |
| Q1 2022 | $5,544,000 | -25.8% | 1,111,112 | 0.0% | 1.40% | -3.7% |
| Q4 2021 | $7,467,000 | +22.6% | 1,111,112 | 0.0% | 1.45% | +51.7% |
| Q3 2021 | $6,089,000 | -16.2% | 1,111,112 | 0.0% | 0.96% | +6.5% |
| Q2 2021 | $7,267,000 | -21.8% | 1,111,112 | 0.0% | 0.90% | -47.6% |
| Q1 2021 | $9,289,000 | +19.4% | 1,111,112 | 0.0% | 1.71% | +119.1% |
| Q4 2020 | $7,778,000 | +12.2% | 1,111,112 | 0.0% | 0.78% | -59.6% |
| Q3 2020 | $6,933,000 | +3315.3% | 1,111,112 | +2456.9% | 1.93% | +2875.4% |
| Q2 2020 | $203,000 | – | 43,456 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
| Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
| Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
| Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
| Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
| NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
| Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
| Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
| ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
| Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |